Abstract
Broad-based prospective sequencing has begun to inform the care of individual cancer patients. Such genomically driven cancer medicine is facilitating the use of mechanism-based therapeutic approaches in patients. In addition to the value of such data to inform the treatment of individual patients under active clinical care, over time these accrue as unprecedented datasets of integrated genomic, clinical, and treatment response data that can inform translational cancer research. Here, we present preliminary results of our efforts to combine both large-scale retrospective and prospective sequencing data in cancer to drive translational cancer biology. We will report on our efforts to develop a computational oncology framework to mine these data not only for new treatment hypotheses that can be tested clinically and the preliminary results from those studies, but also how this is driving new approaches to understand so-called long tail mutations both biologically and clinically. These efforts lie at the interface of retrospective and prospective studies to inform precision oncology through new tools that move beyond enumerating individual genetic vulnerabilities toward interpreting their biological and clinical interpretation for the benefit of patients.
Citation Format: Barry S. Taylor. Clinical genomics alters care, informs new science. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy; Jun 13-16, 2015; Salt Lake City, UT. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(1_Suppl):Abstract nr IA05.
RSS Feeds